An observational, specified, and non-specified clinical study to assess the safety and efficacy of cannabidiol (CBD) and cannabigerol (CBG) formulations in patients with nocturia, using diagnostic indicators. (An observational, specified, and non-specified clinical study to assess the safety and efficacy of cannabidiol (CBD) and cannabigerol (CBG) formulations in patients with nocturia, using diagnostic indicators.)

未提供0 个研究点目标入组 10 人开始时间: 待定

适应症

试验速览

暂无简介。

•Men and women aged 20 to 80 years old
•Patients with nocturia (defined as waking up to urinate more than twice during sleep)
•Patients for whom standard medications have not been effective
•Cases deemed appropriate by the principal investigator or co-investigator

•A. Exclusions due to medical history, concomitant use, or physician's discretion
•Patients who had a hypersensitivity or allergic reaction to CBD or CBG preparations and were unable to continue the study.
•Patients taking other medications concomitantly.
•Patients who have previously participated in clinical trials and have not yet taken the study drug for more than one month.
•Patients who the principal investigator or co-investigator deems inappropriate for inclusion.
•B. Exclusions due to underlying diseases or physical conditions
•Severe liver damage
•Cardiac dysfunction
•Renal dysfunction
•Breastfeeding
•Symptomatic urinary tract infection
•Multiple sclerosis, spinal cord injury, or Parkinson's disease

发起方

未提供